TOP > 外国特許検索 > PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR

PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR

外国特許コード F180009340
整理番号 S2016-0413-C0
掲載日 2018年3月13日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP004552
国際公開番号 WO 2017138557
国際出願日 平成29年2月8日(2017.2.8)
国際公開日 平成29年8月17日(2017.8.17)
優先権データ
  • 特願2016-022081 (2016.2.8) JP
発明の名称 (英語) PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR
発明の概要(英語) [Problem] To provide a technique relating to a therapy for an immune-checkpoint inhibitor-resistant tumor. [Solution] The problem can be solved by a pharmaceutical composition which is intended to be administered prior to the administration of T cells specific to an antigen in a T cell infusion therapy for an immune-checkpoint inhibitor-resistant tumor, said pharmaceutical composition containing an antigen-encapsulated nano gel, wherein the antigen-encapsulated nano gel comprises a long-chain peptide antigen or a protein antigen each of which is encapsulated in a hydrophobized polysaccharide nano gel, and the long-chain peptide antigen or the protein antigen contains a CD8-positive cytotoxic T cell-recognizing epitope and a CD4-positive helper T cell-recognizing epitope both originated from the aforementioned antigen.
特許請求の範囲(英語) [claim1]
1. T cell immune checkpoint inhibitor in transfusion therapy resistant tumor, T specific to an antigen administered to the cells prior to administration of the pharmaceutical composition wherein said antigen is derived from a CD8 - positive cells and/or cytotoxic helper-cell recognized epitopes T T CD4 positive comprises a long-chain-cell recognized epitopes of the peptide antigen or protein antigen is hydrophobized polysaccharide and antigen NANOTRACK NANOTRACK LPHs LPHs gel pharmaceutical composition containing a gel.
[claim2]
2. T cells relative to immune checkpoint inhibitor in transfusion therapy resistant tumor, wherein the antigen is administered after administration of the gel on the nanoparticles with said T cells specific for an antigen in a pharmaceutical composition comprising, wherein said antigen is an antigen derived from a nano-gel mounted on CD8 - positive cytotoxic helpersolid T T/or CD4 positive cell recognized epitopes and comprises a long-chain-cell recognized epitopes of the peptide antigen is a polysaccharide or a protein antigen which is mounted on a hydrophobic gel nanoparticles of the pharmaceutical composition.
[claim3]
3. Further, immune enhancing agent is administered with an antigen on a gel nanoparticles, nano-antigen or an immune enhancing agent is included in the gel or on the composition according to claim 2 claim 1.
[claim4]
4. T cells specific for said antigen, wherein the chimeric antigen receptor or antigen recognition T cells T receptor-expressing cell, wherein the composition of any one of the claim 1 - claim 3 1.
[claim5]
5. The long-chain consists of amino acids of the 23-120 antigen is a peptide of any one of the composition according to claim 1 - claim 4 1.
[claim6]
6. T cells contained in the long chain of the peptide antigen of between epitopes recognized, 2-10 three tyrosine, threonine of 2-10, 2-10 histidines, 2-10 2-10 one of glutamine and asparagine that comprises a sequence selected from the group consisting of the composition according to any preceding claim 1 - claim 5 1.
[claim7]
7. Wherein the hydrophobic polysaccharide is pullulan containing cholesteryl and 1 composition according to any one of the claim 1 - claim 6.
[claim8]
8. Wherein the immune enhancing agent, TLR (Toll-like receptor) agonists (Poly-IC RNA DNA or oligo CpG), agonists or RLR STING (like receptor RIG-I) agonist is selected from the group consisting 1 of any one of the at least one composition according to claim 3 - claim 7.
[claim9]
9. Where said antigen is a tumor-specific antigen protein or a protein-specific antigen in the tumor stroma of the composition according to any one of the claim 1 - claim 8 1.
[claim10]
10. Wherein said antigen is mounted on the route of administration of the gel nanoparticles, subcutaneous, intradermal, intramuscular, intratumoral and intravenous and at least one selected from the group consisting of any one of claim 1 - claim 9 1 administered by a route of the composition.
[claim11]
11. Wherein the gel nanoparticles on the antigen, said antigen specific for the administration of a pharmaceutical composition containing the cells and the T at least any one of the claim 1 - claim 10 1 1 prior to the administration of the composition.
[claim12]
12. In which the tumor when administered intravenously to selectively deliver the macrophages of a local delivery system, the hydrophobic polysaccharide pullulan and cholesteryl group less than or equal to 80nm consists of particles having a diameter of the gel.
[claim13]
13. Immune checkpoint inhibitor drug effective in the treatment of a tumor resistance in order to identify a non-human mammalian tumor model, wherein the tumor is a murine sarcoma CMS5a and, the non-human mammal model non-human mammal is a mouse.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MIE UNIVERSITY
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • SHIKU HIROSHI
  • HARADA NAOZUMI
  • MURAOKA DAISUKE
  • AKIYOSHI KAZUNARI
国際特許分類(IPC)
指定国 (WO2017138557)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
さらに詳しい情報をご要望の方は、下記「問合せ先」までお問い合わせください。未公開情報等の交換をおこなう場合は秘密保持契約を締結しての面談等にて対応しております。

PAGE TOP

close
close
close
close
close
close